Literatur
-
1 Fink M P. Shock: An overview. In: Rippe JM, Irwin RS, Fink MP, Cerra FB (Hrsg) Intensive Care Medicine. Boston; Little, Brown and Company 1996: 1857-1877
-
2
Janssens U, Graf J.
Was ist „Schock”.
Internist.
2004;
45
258-266
-
3 Higgins T L, Chernow B. Receptor pyhsiology and pharmacology in circulatory shock. In: Sivak ED, Higgins TL, Seiver A (Hrsg) The High Risk Patient: Management of the Critically Ill. Baltimore; Williams & Wilkins 1995: 1313-1337
-
4
Wollert K C, Drexler H.
Akute Herzinsuffizienz.
Internist (Berl).
1998;
39
459-466
-
5 Blüthgen A. Differenzialdiagnostik des kardialen Versagens. In: Eckart J, Forst H, Burchardi H, Hrsg Intensivmedizin Kompendium und Repetitorium zur interdisziplinären Fort- und Weiterbildung. Landsberg; Ecomed 2002: 1-12
-
6
Cleland J G, Swedberg K, Follath F, Komajda M, Cohen-Solal A, Aguilar J C, Dietz R, Gavazzi A, Hobbs R, Korewicki J, Madeira H C, Moiseyev V S, Preda I, van Gilst W H, Widimsky J, Freemantle N, Eastaugh J, Mason J.
The EuroHeart Failure survey programme - a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis.
Eur Heart J.
2003;
24
442-463
-
7 The Adhere registry .Second quarter 2003 National Benchmark Report. Verfügbar www.adhereregistry.com/national_BMR/Q3_03_National_ADHERE_BMR. pdf
-
8
Adams H A, Baumann G, Gänsslein A, Janssens U, Knoefel W, Koch T, Marx G, Müller-Werdan U, Pape H C, Prange W, Roesner D, Standl T, Teske W, Werner G, Zander R.
Die Definition der Schockformen.
Intensivmed.
2001;
38
541-553
-
9
Acute myocardial infarction: pre-hospital and in-hospital management .
The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology.
Eur Heart J.
1996;
17
43-63
-
10
Hasdai D, Topol E J, Califf R M, Berger P B, Holmes D R Jr.
Cardiogenic shock complicating acute coronary syndromes.
Lancet.
2000;
356
749-756
-
11
Hollenberg S M, Kavinsky C J, Parrillo J E.
Cardiogenic shock.
Ann Intern Med.
1999;
131
47-59
-
12
Hollenberg S M.
Cardiogenic shock.
Crit Care Clin.
2001;
17
391-410
-
13
Menon V, White H, LeJemtel T, Webb J G, Sleeper L A, Hochman J S.
The clinical profile of patients with suspected cardiogenic shock due to predominant left ventricular failure: a report from the SHOCK Trial Registry. SHould we emergently revascularize Occluded Coronaries in cardiogenic shocK?.
J Am Coll Cardiol.
2000;
36 (3 Suppl A)
1071-1076
-
14
Califf R M, Bengtson J R.
Cardiogenic shock.
N Engl J Med.
1994;
330
1724-1730
-
15
Goldberg R J, Samad N A, Yarzebski J, Gurwitz J, Bigelow C, Gore J M.
Temporal trends in cardiogenic shock complicating acute myocardial infarction.
N Engl J Med.
1999;
340
1162-1168
-
16
Hochman J S, Buller C E, Sleeper L A, Boland J, Dzavik V, Sanborn T A, Godfrey E, White H D, Lim J, LeJemtel T.
Cardiogenic shock complicating acute myocardial infarction-etiologies, management and outcome: a report from the SHOCK Trial Registry. SHould we emergently revascularize Occluded Coronaries for cardiogenic shocK.
J Am Coll Cardiol.
2000;
36 (3 Suppl A)
1063-1070
-
17
Hochman J S.
Cardiogenic shock complicating acute myocardial infarction: expanding the paradigm.
Circulation.
2003;
107
2998-3002
-
18
Prondzinsky R, Werdan K, Buerke M.
Kardiogener Schock. Pathomechanismen, klinischer Verlauf, therapeutische Ansätze und Perspektiven.
Internist (Berl).
2004;
45
284-295
-
19
Müller-Werdan U.
Akute septische Kardiomyopathie.
Internist.
1998;
39
467-478
-
20
Müller-Werdan U, Werdan K.
Endorganschäden bei Entzündung und Sepsis.
Internist (Berl).
2003;
44
864-871
-
21
Geppert A, Steiner A, Zorn G, Delle-Karth G, Koreny M, Haumer M, Siostrzonek P, Huber K, Heinz G.
Multiple organ failure in patients with cardiogenic shock is associated with high plasma levels of interleukin-6.
Crit Care Med.
2002;
30
1987-1994
-
22
Mitaka C, Hirata Y, Yokoyama K, Wakimoto H, Hirokawa M, Nosaka T, Imai T.
Relationships of circulating nitrite/nitrate levels to severity and multiple organ dysfunction syndrome in systemic inflammatory response syndrome.
Shock.
2003;
19
305-309
-
23 Drexler H, von Bonin J. Kardiogener Schock nach Myokardinfarkt: Therapieansätze. In: Eckart J, Forst H, Burchardi H, Hrsg Intensivmedizin Kompendium und Repetitorium zur interdisziplinären Fort- und Weiterbildung. Landsberg; Ecomed 2002: 1-12
-
24
De Backer D, Creteur J, Dubois M J, Sakr Y, Vincent J L.
Microvascular alterations in patients with acute severe heart failure and cardiogenic shock.
Am Heart J.
2004;
147
91-99
-
25
Janssens U.
Hämodynamisches Monitoring.
Internist.
2000;
41
995-1010
-
26
Cotter G, Moshkovitz Y, Kaluski E, Milo O, Nobikov Y, Schneeweiss A, Krakover R, Vered Z.
The role of cardiac power and systemic vascular resistance in the pathophysiology and diagnosis of patients with acute congestive heart failure.
Eur J Heart Fail.
2003;
5
443-451
-
27
Fincke R, Hochman J S, Lowe A M, Menon V, Slater J N, Webb J G, LeJemtel T H, Cotter G.
Cardiac power is the strongest hemodynamic correlate of mortality in cardiogenic shock: a report from the SHOCK trial registry.
J Am Coll Cardiol.
2004;
44
340-348
-
28 Janssens U. Management des kardiogenen Schocks. In: Kuhlen R, Putensen Ch, Quintel M (Hrsg) Jahrbuch Intensivmedizin 2004. Lengerich; Pabst Science Publishers 2004: 88-104
-
29
Consensus Conference .
Pulmonary Artery Catheter Consensus Conference: Consensus statement.
Crit Care Med.
1997;
25
910-925
-
30
Goedje O, Hoeke K, Lichtwarck-Aschoff M, Faltchauser A, Lamm P, Reichart B.
Continuous cardiac output by femoral arterial thermodilution calibrated pulse contour analysis: comparison with pulmonary arterial thermodilution.
Crit Care Med.
1999;
27
2407-2412
-
31
Hollenberg S M, Kavinsky C J, Parrillo J E.
Cardiogenic shock.
Ann Intern Med.
1999;
131
47-59
-
32
Krivokuca M, Werdan K.
Therapie der akuten Herzinsuffizienz. Notfalltherapie.
Internist (Berl).
2000;
41 (2 Pt 1)
127-136
-
33
Hochman J S, Sleeper L A, Webb J G, Sanborn T A, White H D, Talley J D, Buller C E, Jacobs A K, Slater J N, Col J, McKinlay S M, LeJemtel T H.
Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK Investigators. Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock [see comments].
N Engl J Med.
1999;
341
625-634
-
34
Hochman J S, Sleeper L A, White H D, Dzavik V, Wong S C, Menon V, Webb J G, Steingart R, Picard M H, Menegus M A, Boland J, Sanborn T, Buller C E, Modur S, Forman R, Desvigne-Nickens P, Jacobs A K, Slater J N, LeJemtel T H.
One-year survival following early revascularization for cardiogenic shock.
JAMA.
2001;
285
190-192
-
35
Panacek E A, Kirk J D.
Role of noninvasive ventilation in the management of acutely decompensated heart failure.
Rev Cardiovasc Med.
2002;
3 (Suppl 4)
S35-S40
-
36
Mehta S, Jay G D, Woolard R H, Hipona R A, Connolly E M, Cimini D M, Drinkwine J H, Hill N S.
Randomized, prospective trial of bilevel versus continuous positive airway pressure in acute pulmonary edema.
Crit Care Med.
1997;
25
620-628
-
37
Hunt S A, Baker D W, Chin M H, Cinquegrani M P, Feldman A M, Francis G S, Ganiats T G, Goldstein S, Gregoratos G, Jessup M L, Noble R J, Packer M, Silver M A, Stevenson L W, Gibbons R J, Antman E M, Alpert J S, Faxon D P, Fuster V, Jacobs A K, Hiratzka L F, Russell R O, Smith S C Jr.
ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to revise the 1995 Guidelines for the Evaluation and Management of Heart Failure).
J Am Coll Cardiol.
2001;
38
2101-2113
-
38
Fonarow G C.
The treatment targets in acute decompensated heart failure.
Rev Cardiovasc Med.
2001;
2 (Suppl 2)
S7-S12
-
39
Cotter G, Metzkor E, Kaluski E, Faigenberg Z, Miller R, Simovitz A, Shaham O, Marghitay D, Koren M, Blatt A, Moshkovitz Y, Zaidenstein R, Golik A.
Randomised trial of high-dose isosorbide dinitrate plus low-dose furosemide versus high-dose furosemide plus low-dose isosorbide dinitrate in severe pulmonary oedema.
Lancet.
1998;
351
389-393
-
40
Haghi D, Borggrefe M, Süselbeck T, Wolpert C.
Medikamente zur Therapie kardialer Ödeme.
J Kardiol.
2004;
4
158-164
-
41
Bindels A J, van der Hoeven J G, Meinders A E.
Pulmonary artery wedge pressure and extravascular lung water in patients with acute cardiogenic pulmonary edema requiring mechanical ventilation.
Am J Cardiol.
1999;
84
1158-1163
-
42
Sacchetti A, Ramoska E, Moakes M E, McDermott P, Moyer V.
Effect of ED management on ICU use in acute pulmonary edema.
Am J Emerg Med.
1999;
17
571-574
-
43
Fonarow G C.
B-type natriuretic peptide: spectrum of application. Nesiritide (recombinant BNP) for heart failure.
Heart Fail Rev.
2003;
8
321-325
-
44
Colucci W S, Elkayam U, Horton D P, Abraham W T, Bourge R C, Johnson A D, Wagoner L E, Givertz M M, Liang C S, Neibaur M, Haught W H, LeJemtel T H.
Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group.
N Engl J Med.
2000;
343
246-253
-
45
Publication Committee for the VMAC Investigators (Vasodilatation in the Management of Acute CHF) .
Intravenous nesiritide vs. nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial.
JAMA.
2002;
287
1531-1540
-
46
Khot U N, Novaro G M, Popovic Z B, Mills R M, Thomas J D, Tuzcu E M, Hammer D, Nissen S E, Francis G S.
Nitroprusside in critically ill patients with left ventricular dysfunction and aortic stenosis.
N Engl J Med.
2003;
348
1756-1763
-
47
Torre-Amione G, Young J B, Colucci W S, Lewis B S, Pratt C, Cotter G, Stangl K, Elkayam U, Teerlink J R, Frey A, Rainisio M, Kobrin I.
Hemodynamic and clinical effects of tezosentan, an intravenous dual endothelin receptor antagonist, in patients hospitalized for acute decompensated heart failure.
J Am Coll Cardiol.
2003;
42
140-147
-
48
Udelson J E, Smith W B, Hendrix G H, Painchaud C A, Ghazzi M, Thomas I, Ghali J K, Selaru P, Chanoine F, Pressler M L, Konstam M A.
Acute hemodynamic effects of conivaptan, a dual V(1A) and V(2) vasopressin receptor antagonist, in patients with advanced heart failure.
Circulation.
2001;
104
2417-2423
-
49
Lee C R, Watkins M L, Patterson J H, Gattis W, O’Connor C M, Gheorghiade M, Adams K F Jr.
Vasopressin: a new target for the treatment of heart failure.
Am Heart J.
2003;
146
9-18
-
50
Cotter G, Kaluski E, Milo O, Blatt A, Salah A, Hendler A, Krakover R, Golick A, Vered Z.
LINCS: L-NAME (a NO synthase inhibitor) in the treatment of refractory cardiogenic shock: a prospective randomized study.
Eur Heart J.
2003;
24
1287-1295
-
51
Böhm M.
Pathophysiologie der Herzinsuffizienz heute.
Herz.
2002;
27
75-91
-
52
Gauss A, Anhaupl T, Schutz W.
Grundzüge der Katecholamintherapie. Teil 1: Charakterisierung der therapeutisch bedeutsamen Sympathomimetika.
Anasthesiol Intensivmed Notfallmed Schmerzther.
2000;
35
131-136
-
53
Adams H A, Bauer M, Baumann G, Cascorbi I, Geiger S, Janssens U, Klippe H J, Knoefel W T, Müller-Werdan U, Prange W, Schareck W, Schürholz T, Standl T, Teske W, Werner G, Windolf J, Zander R.
Therapie des kardialen Schocks.
Intensivmed.
2004;
in press
-
54
Cuffe M S, Califf R M, Adams K F Jr, Benza R, Bourge R, Colucci W S, Massie B M, O’Connor C M, Pina I, Quigg R, Silver M A, Gheorghiade M.
Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial.
JAMA.
2002;
287
1541-1547
-
55
Delle K G, Heinz G.
Levosimendan in Kardiologie und Intensivmedizin.
Wien Klin Wochenschr.
2004;
116
6-14
-
56
Slawsky M T, Colucci W S, Gottlieb S S, Greenberg B H, Haeusslein E, Hare J, Hutchins S, Leier C V, LeJemtel T H, Loh E, Nicklas J, Ogilby D, Singh B N, Smith W.
Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Study Investigators.
Circulation.
2000;
102
2222-2227
-
57
Moiseyev V S, Poder P, Andrejevs N, Ruda M Y, Golikov A P, Lazebnik L B, Kobalava Z D, Lehtonen L A, Laine T, Nieminen M S, Lie K I.
Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN).
Eur Heart J.
2002;
23
1422-1432
-
58
Follath F, Cleland J G, Just H, Papp J G, Scholz H, Peuhkurinen K, Harjola V P, Mitrovic V, Abdalla M, Sandell E P, Lehtonen L.
Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial.
Lancet.
2002;
360
196-202
-
59
Delle K G, Buberl A, Geppert A, Neunteufl T, Huelsmann M, Kopp C, Nikfardjam M, Berger R, Heinz G.
Hemodynamic effects of a continuous infusion of levosimendan in critically ill patients with cardiogenic shock requiring catecholamines.
Acta Anaesthesiol Scand.
2003;
47
1251-1256
-
60
Low R.
Intra-aortic balloon counterpulsation in acute myocardial infarction: too few or too many?.
J Am Coll Cardiol.
2003;
41
1946-1947
-
61
Van de W F, Ardissino D, Betriu A, Cokkinos D V, Falk E, Fox K A, Julian D, Lengyel M, Neumann F J, Ruzyllo W, Thygesen C, Underwood S R, Vahanian A, Verheugt F W, Wijns W.
Management of acute myocardial infarction in patients presenting with ST-segment elevation. The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology.
Eur Heart J.
2003;
24
28-66
-
62
Siostrzonek P.
Akutintervention und Ballonpumpe.
J Kardiol.
2004;
11
34-35
-
63
Hochman J S, Sleeper L A, Webb J G, Sanborn T A, White H D, Talley J D, Buller C E, Jacobs A K, Slater J N, Col J, McKinlay S M, LeJemtel T H.
Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK Investigators. Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock.
N Engl J Med.
1999;
341
625-634
PD Dr. med. U. Janssens
Innere Medizin
St. Antonius Hospital Eschweiler · Dechant-Deckers-Straße · 52249 Eschweiler ·
Email: uwe.janssens@post.rwth-aachen.de
